Home   /  Find a Trial  /  See All TrialsHELP /  AYUDA /  求助 : (415) 476-5777 | Click to print page Print
 

See All Trials

QuickViews

Match by Tumor Type:

Treatment:

Newly Diagnosed (Stage I-III)
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)
Inflammatory Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

Advanced/Metastatic Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

Sites with evidence of disease:

View by Trial Type:

Treatment:

 

Non-Treatment:

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter
Twitter

 
Having Children

Helping Parents Talk to Their School-Age Children About Cancer

Enhancing Connections Telephone Program: A Cancer Education Program for Parents (NCT02129049)

Summary

A cancer diagnosis can cause emotional distress in both parents and children. But it can be difficult for parents to talk to their children about their cancer or support their children while undergoing cancer treatment. Studies have found that the Enhancing Connections Program, an in-person educational program, can decrease parents' depression and anxiety; improve parenting quality, parenting skills and confidence; and enhance the child's behavioral-emotional adjustment. Providing this education program by telephone may help parents talk with their school-age children about their cancer. This trial is investigating the effectiveness of using the Enhancing Connections Program by telephone to improve communication between patients with early stage cancer and their children. To be eligible, participants must have had a diagnosis of stage 0-III breast cancer within the last seven months.

Sexual and Reproductive Health Study

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma (NCT01788839)

Summary

Cancer and its treatment may affect sexual and reproductive health. To help researchers learn more about the problems women face, participants in this study will complete questionnaires on sexuality and pregnancy before, during, and after cancer treatment. The information will be used to help doctors identify which women are most likely to have early menopause or develop sexual problems during cancer therapy, or have difficulty getting pregnant after cancer treatment. To be eligible for this study a woman must be age 50 or younger, newly diagnosed with breast cancer, and planning on having, or within one month of starting, chemotherapy.

Evaluating the Effects of Chemotherapy on Ovarian Function

Multi-Center Study of Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer and Lymphoma (NCT00823654)

Summary

Breast cancer treatments can affect the ovaries, making it difficult for a woman to later conceive a child. They can also bring on early menopause. Ovarian functioning can be assessed by evaluating the blood levels of certain hormones the ovaries produce. The purpose of this study is to see how different cancer treatments affect the ovaries, and whether there are ways to predict which women will be more likely to go into early menopause. Women planning to have treatment with chemotherapy (CMF or ACT) or hormone therapy (tamoxifen) are eligible for this study. Women without cancer who are being treated at the NY Medical College/Center for Human Reproduction are also eligible.

Improving Fertility Preservation

A Randomized Open Label Clinical Trial of Fixed Dose Letrozole vs. Titrated Letrozole for In Vitro Fertilization With Cryopreservation of Oocytes and Embryos in Breast Cancer Patients (NCT01035099)

Summary

Some breast cancer treatments may affect a woman's ability to become pregnant. Women can choose to undergo in vitro fertilization (IVF) prior to chemotherapy or radiation so that they can store their eggs and try to become pregnant at a later date. IVF involves ovarian stimulation and egg retrieval. Conventional ovarian stimulation often results in very high estrogen levels, which may be unsafe for breast cancer patients. Letrozole (Femara®) is an aromatase inhibitor used to treat hormone-sensitive tumors in postmenopausal women. It can reduce estrogen levels during IVF while still allowing for effective ovarian stimulation. This trial will compare the effectiveness of two different ways of administering letrozole during ovarian stimulation in patients who are scheduled to undergo IVF for fertility preservation due to breast cancer.